β-defensin-3 promoted osteosarcoma progression via activating the PI3K/AKT pathway and regulated tumor immune response
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-06 · 399 (9) · 14421-14437
DOI: 10.1007/s00210-026-05294-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 15.04.2026. Verfasst von Kang Zou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Osteopathy and Bone Oncology, Yantaishan Hospital, No. 10087, Keji Avenue, Laishan District, Yantai, Shandong, 264043, China. Hauptthemen laut MEDLINE: Osteosarcoma, Proto-Oncogene Proteins c-akt, beta-Defensins, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
This study investigated the role of human β-defensin-3 (HBD-3) in osteosarcoma and its underlying molecular and immunological mechanisms. HBD-3 was overexpressed or knocked down in MG63 and MNNG/HOS cells, and cell proliferation, apoptosis, and cell cycle were detected. PI3K/AKT agonists (740Y-P, SC79) were used for mechanism exploration. In vivo, MG63-bearing nude mouse models were used to monitor tumor growth and survival, and LM8-bearing C57BL/6 models to evaluate immune responses. Flow cytometry was used to detect the proportion and functional status of specific T cells and dendritic cells (DCs) in spleen and tumor tissues. HBD-3 was highly expressed in MG63 and MNNG/HOS cells. Functional assays showed that HBD-3 overexpression significantly promoted osteosarcoma cell proliferation and suppressed apoptosis, while HBD-3 knockdown induced G0/G1 phase cell cycle arrest, inhibited cell proliferation, and enhanced apoptosis. Mechanistically, HBD-3 overexpression activated the PI3K/AKT signaling pathway and increased the phosphorylation level of FOXO3A. In contrast, HBD-3 silencing attenuated PI3K/AKTactivation, reduced FOXO3A phosphorylation, and facilitated its nuclear translocation-indicating that the regulatory effect of HBD-3 on osteosarcoma cells was partly dependent on the PI3K/AKT pathway. Furthermore, HBD-3 knockdown promoted DC maturation and enhanced CD8 T cell activation in the tumor microenvironment, thereby reshaping the anti-tumor immune response. Collectively, our findings demonstrated that HBD-3 exerts its oncogenic functions partly via the PI3K/AKT/FOXO3A pathway to drive malignant progression. Moreover, HBD-3 participates in regulating the tumor anti-tumor immune response. These results identify HBD-3 as a potential novel therapeutic target for osteosarcoma treatment, and targeted inhibition of HBD-3 may become a promising strategy for osteosarcoma immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Osteopathy and Bone Oncology, Yantaishan Hospital, No. 10087, Keji Avenue, Laishan District, Yantai, Shandong, 264043, China.
- Department of Osteopathy and Bone Oncology, Yantaishan Hospital, No. 10087, Keji Avenue, Laishan District, Yantai, Shandong, 264043, China. 13356387775@163.com.
Zitieren
APA
Zou, K., & Wang, K. (2026). β-defensin-3 promoted osteosarcoma progression via activating the PI3K/AKT pathway and regulated tumor immune response. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(9), 14421-14437. https://doi.org/10.1007/s00210-026-05294-w
Vancouver
Zou K, Wang K. β-defensin-3 promoted osteosarcoma progression via activating the PI3K/AKT pathway and regulated tumor immune response. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(9):14421-14437. doi:10.1007/s00210-026-05294-w
BibTeX
@article{Zou2026,
author = {Zou, Kang and Wang, Ke},
title = {β-defensin-3 promoted osteosarcoma progression via activating the PI3K/AKT pathway and regulated tumor immune response},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {9},
pages = {14421--14437},
doi = {10.1007/s00210-026-05294-w}
}
EUVIMED